As the number of diabetics climbs, insulin drug research and development companies are also increasing investment
.
It is understood that there are seven main categories of common oral hypoglycemic drugs on the market, and the characteristics of different hypoglycemic drugs are different
.
Among them, DPP-4 inhibitors are new types of oral diabetes medications listed in recent years, and their status in the hypoglycemic industry is currently rising
.
The data shows that in recent years, the sales of domestic DPP-4 inhibitors have grown rapidly, and the overall scale of the three terminal and 6 major markets in 2021 has exceeded 4 billion yuan, and the proportion of the terminal diabetes drug market in public hospitals in key provinces and cities in the first quarter of 2022 has reached more than
10% again.
At the same time, the domestic array of innovative drugs and generic drugs is also expanding
.
For example, recently, the research and development of new drugs for new oral hypoglycemic drugs SUCH-4 inhibitors has ushered in good news
.
On August 25, HiSco issued an announcement that the company's Class 1 new drug HSK7653 tablets have completed two Phase III clinical trials and reached the preset end point, and the company will submit a listing application to NMPA as soon as possible in accordance with relevant regulations
.
If HSK7653 tablets are successfully approved for marketing, it will become the world's first bi-weekly preparation of hypoglycemic drugs, and hisco's currently listed products do not involve diabetes medication
.
On August 22, CSPC Pharmaceutical Group announced that two key clinical trials of a new class of drugs "plumagliptin tablets" ("DBPR108 tablets") of the company's subsidiary CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co.
, Ltd.
for the treatment of type 2 diabetes have reached preset endpoints
.
It is understood that DBPR108 tablets are a new type of oral dipeptidase-IV.
(DPP-4) inhibitor, which has high selectivity and strong inhibition of
DPP-4.
By inhibiting DPP-4, the endogenous active glucagon-like peptide-1 (GLP-1) level is increased, the sensitivity of β cells and α cells to glucose is enhanced, the glucose-stimulated insulin secretion is increased and the inhibitory effect of glucose on glucranin secretion is enhanced, thereby reducing blood glucose levels
.
It is worth mentioning that Gan&Lee Pharmaceutical also said at the recent performance briefing that the company will actively promote the first self-developed oral hypoglycemic drug on the market - siglitine phosphate tablets to participate in the domestic substitution process
of DPP-4 inhibitors.
In addition to the above enterprises, at present, East China Pharmaceutical, Microchip Bio, Aosaikang, Qilu, Dongguang Pharmaceutical and other enterprises are also accelerating the layout of DPP-4 inhibitors
.
It is understood that before 2019, the era of monopoly of multinational pharmaceutical companies in this field was established; As domestic pharmaceutical companies continue to increase their entry, especially after Aosaicon's saxagliptin tablets became the first approved domestic DPP-4 inhibitor in 2019, domestic generic drugs have entered an outbreak era
.
The data shows that 2020 and 2021 are the approved blowout period, and the number of approved domestic DPP-4 inhibitor approvals is 73, involving 6 major products
.
The industry expects that after 2022 or 2023, this type of hypoglycemic drugs will enter the era of
domestic class 1 new drugs blowout.
With the continuous innovation of domestic brands, the pattern of such oral hypoglycemic drugs is about to change dramatically
.
